{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
| image = Idoxifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = Acute: 15 hours<ref name="AdisInsight" /><br />Chronic: 23 days<ref name="AdisInsight" />
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 116057-75-1
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3034011
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 2298565
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 456UXE9867
| KEGG = D04496
| ChEBI = 
| ChEMBL = 6318

<!--Chemical data-->
| C=28 | H=30 | I=1 | N=1 | O=1
| molecular_weight = 523.458 g/mol
| SMILES = CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\C3=CC=C(C=C3)I)/C4=CC=CC=C4
| StdInChI_Ref = 
| StdInChI = 1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-
| StdInChIKey_Ref = 
| StdInChIKey = JJKOTMDDZAJTGQ-DQSJHHFOSA-N
| synonyms = CB-7432, SB-223030; Pyrrolidino-4-iodotamoxifen; 4-Iodopyrrolidinotamoxifen
}}

'''Idoxifene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (former developmental code names '''CB-7432''', '''SB-223030'''), also known as '''pyrrolidino-4-iodotamoxifen''', is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group which was under development for the treatment of [[breast cancer]] and [[menopause|postmenopausal]] [[osteoporosis]] but was never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800003448{{dead link|date=April 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref name="MillerIngle2002">{{cite book|author1=William R. Miller|author2=James N. Ingle|title=Endocrine Therapy in Breast Cancer|url=https://books.google.com/books?id=00_LBQAAQBAJ&pg=PA58|date=8 March 2002|publisher=CRC Press|isbn=978-0-203-90983-6|pages=58–}}</ref><ref name="pmid2585441">{{cite journal | vauthors = McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, Foster AB | title = Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent | journal = J. Med. Chem. | volume = 32 | issue = 12 | pages = 2527–33 | year = 1989 | pmid = 2585441 | doi = | url = }}</ref> It reached [[Phases of clinical research#Phase II|phase III]] [[clinical trial]]s for postmenopausal osteoporosis and [[Phases of clinical research#Phase II|phase II]] clinical trials for breast cancer before development was discontinued in 1999 due insufficient [[effectiveness]] in both cases.<ref name="AdisInsight" />

==Chemistry==

===Synthesis===
A large-scale [[chemical synthesis]] of idoxifene has been devised.<ref name="McCaguePotter1994">{{cite journal|last1=McCague|first1=Raymond|last2=Potter|first2=Gerard A.|last3=Jarman|first3=Michael|title=AN EFFICIENT, LARGE-SCALE SYNTHESIS OF IDOXIFENE {(E)-1-[4-[2-(N-PYRROLIDINO)ETHOXY]PHENYL]-1-(4-IODOPHENYL)-2-PHENYL-1-BUTENE}|journal=Organic Preparations and Procedures International|volume=26|issue=3|year=1994|pages=343–346|issn=0030-4948|doi=10.1080/00304949409458432}}</ref>

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800003448 Idoxifene - AdisInsight]


{{Estrogen receptor modulators}}

[[Category:Hormonal antineoplastic drugs]]
[[Category:Iodoarenes]]
[[Category:Phenol ethers]]
[[Category:Pyrrolidines]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]
[[Category:Abandoned drugs]]


{{genito-urinary-drug-stub}}
{{antineoplastic-drug-stub}}